Media Center
Home»Media Center»Press Releases

Press Releases

2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
December 13, 2012 Impax Laboratories Names Bryan M. Reasons as Chief Financial Officer
November 21, 2012 Impax Laboratories Enters Into Development, Manufacturing and Commercialization Agreement with Perrigo
November 20, 2012 Impax Laboratories to Present at the Piper Jaffray 24th Annual Healthcare Conference
November 16, 2012 Impax Laboratories and ThoRx Laboratories Confirm Patent Challenge Relating to Generic OPANA® ER 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg
November 8, 2012 Impax Laboratories to Present at the Credit Suisse 2012 Healthcare Conference
October 30, 2012 Impax Laboratories Reports Third Quarter 2012 Results
October 12, 2012 Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date to January 21, 2013
October 10, 2012 Impax Laboratories Announces Time Change for Third Quarter 2012 Earnings Conference Call on October 30
October 9, 2012 Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2012 Financial Results
September 17, 2012 Impax Laboratories to Present at the UBS Global Life Sciences Conference
September 14, 2012 Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA®
September 4, 2012 Impax Laboratories Announces Settlement of Litigation Relating to RENVELA® and RENAGEL®
July 31, 2012 Impax Laboratories Reports Second Quarter 2012 Adjusted EPS Increased to $0.60; GAAP EPS Increased to $0.27
July 10, 2012 Impax Laboratories Schedules Conference Call and Webcast for Second Quarter 2012 Financial Results
June 29, 2012 Impax Laboratories Announces Resignation of Arthur A. Koch
June 26, 2012 Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.
June 14, 2012 Impax Laboratories to Present at the Wells Fargo Securities Healthcare Conference
June 4, 2012 Impax Laboratories to Present at the Goldman Sachs Annual Global Healthcare Conference
May 22, 2012 Impax Laboratories Announces Voting Results from 2012 Annual Meeting of Stockholders
May 10, 2012 Impax Laboratories to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 1, 2012 Impax Laboratories Reports Adjusted First Quarter 2012 EPS of $0.52; GAAP EPS of $0.18
April 18, 2012 Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference
April 12, 2012 Impax Laboratories Confirms Patent Challenge Relating to Generic GRALISE® 300 mg and 600 mg
April 4, 2012 Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2012 Financial Results
March 26, 2012 Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.
March 1, 2012 Impax Laboratories to Present at the Cowen and Company Health Care Conference
February 28, 2012 Impax Laboratories Fourth Quarter 2011 EPS Increases 74% to $0.33
February 24, 2012 Impax Laboratories to Present at the RBC Capital Markets’ Healthcare Conference
February 23, 2012 FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease
February 9, 2012 Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility
February 1, 2012 Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights to Zomig® (zolmitriptan) from AstraZeneca
January 26, 2012 Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2011 Financial Results
January 4, 2012 Impax Laboratories to Present at the J.P. Morgan Healthcare Conference

Related Links

Investor Toolkit
Copyright © 2011 Impax Laboratories, Inc. All rights reserved.
Name*  
E-mail*  
Comments
Powered By Q4 Web Systems 3.8.1.5343